Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell: three (3) up sessions and counting

October 17, 2019 6:25pm

Volume (versus 3 month averages) is still low along with percentage moves

While the IBB closed up +0.68% and the XBI closed up +0.86% with the Advance/Decline (A/D) line fattening to 25/17 from yesterday’s 23/19

In compiling my indication signals, I draw on logic, historical precedents, specific knowledge of the sector and its practices as to lessons learned. It’s important for investors to identify and determine which indication is actually performance based.

Will Icarus be flying tomorrow ... ?

While many talk about the shift in alternating sentiment, I monitor the pulse and focus of possible outcomes

The Dow closed points UP +23.90 (+0.09%), the S&P closed + 8.26 points (+0.28%) and the NASDAQ closed UP +32.67 points (+0.40%)

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

Thursday the IBB closed up +0.68% while the XBI closed up +0.86%
Wednesday the IBB closed down -0.11% while the XBI closed down -0.13%
Tuesday the IBB closed up +1.84% while the XBI closed up +1.91%
Monday the IBB closed up +0.38% while the XBI closed down -0.18%

The advance/decline line scenario of 45 covered companies:

Thursday the close was positive with an A/D line of 25/17, 0 flat, 1 reversed merged (HSGX) and 2 acquired;
Wednesday the close was positive with an A/D line of 23/19, 0 flat, 1 reversed merged (HSGX) and 2 acquired;
Tuesday the close was positive with an A/D line of 32/9, 1 flat, 1 reversed merged (HSGX) and 2 acquired;
Monday the close was negative with an A/D line of 12/28, 2 flats, 1 reversed merged (HSGX) and 2 acquired;

Henry’omics:

Sector equities rose on Thursday after strong earnings results from companies such as Netflix and Morgan Stanley. Investors also digested news of European Union and the U.K. striking a deal on Brexit.

Investor expectations are getting apprehensive as BioMarin Pharmaceuticals (BMRN) kicks off our earnings “rounds” on 10/23!

Investor uncertainty heightens surrounded by concerns about the talks of U.S. and Chinese officials, the political climate of our hate spewing media, the health of our markets and the global economy.

Even with Brexit looking promising and a trade deal with China in the works, some investors have doubts it will be clear sailing for stocks the rest of the year without more help from the Federal Reserve <CNBC>.

Global economic data points to slower growth, while the U.S. manufacturing sector is already contracting.

I see a lack of capacity and abilities of “our universe” i.e. sector to manufacture having to out-source these capabilities for supply clinical grade materials for trials and post approval to supply for long term demands as BLAs are approved (like Mesoblast <MESO>).

I am MORE apprehensive re expectation, estimates and forecasts of LPS (Loss-per-Share) numbers as they are released as well as the …tone of conference calls (especially about internal operating issues) that are the read-between-the-lines or rumors (that usually turn out true) – it’s about the confidence perceived in these calls!

Decliners:

ReNeuron (RENE.L -$4.00 after Wednesday’s +$14.00, Tuesday’s -$16,50, Monday’s -$24.50, Friday’s -$4.00 and last Thursday’s +$3.50;
Ionis Pharmaceuticals (IONS -$1.08 after Wednesday’s -$3.84 and Tuesday’s -$1.07);
Intrexon (XON -$0.34);
bluebird bio (BLUE -$0.29 after Wednesday’s +$2.07);
Homology Medicines (FIXX -$0.28 after Wednesday’s -$0.62);

Incliners:

Sage Therapeutics (SAGE +$4.02 after Wednesday’s -$3.45, Tuesday’s +$4.93, Monday’s -$1.22, Friday’s +$4.58 and last Thursday’s -$1.33);
Global Blood therapeutics (GBT +0.89);
Spark therapeutics (ONCE +$0.87 after Wednesday’s +$1.04);
uniQure (QURE +$0.71 after Wednesday’s -$0.98 and Tuesday’s -$2.89);
Regenxbio (RGNX +$0.64);

The percentage (%) indicators:

Thursday’s range of the 25 upside was +0.31% (ONVO) to +2.85% (SAGE) while the 17 downside ranged from -0.06% () to -6.16% (XON);

Wednesday’s range of the 23 upside was +0.20% (VCEL) to +11.11% (RENE.L) while the 19 downside ranged from -0.40% (NTLA) to -6.25% (IONS);

Tuesday’s range of the 32 upside was +0.27% (PSTI) to +8.36% (RGNX) while the 9 downside ranged from -0.12% (BLFS) to -19.74% (KOOL);

Monday’s range of the 12 upside was +0.22% (ALNY) to +15.12% (ADVM) while the 28 downside ranged from -0.09% (GBT) to -14.67% (RENE.L);

Upside volume stats: to compare

Thursday: 3 out of the 25 upside had higher than the 3 month average volume;
Wednesday: 2 out of the 23 upside had higher than the 3 month average volume;
Tuesday: 4 out of the 32 upside had higher than the 3 month average volume;
Monday: 3 out of the 12 upside had higher than the 3 month average volume;

Downside volume stats:

Thursday: 5 out of the 17 downside had higher than the 3 month average volume;
Wednesday: 3 out of the 19 downside had higher than the 3 month average volume;
Tuesday: 3 out of the 9 downside had higher than the 3 month average volume;
Monday: 2 out of the 28 downside had higher than the 3 month average volume;

0 flat with 1 reverse merged (HSGX), 2 acquired (AST & OSIR) and Spark Therapeutics’ (ONCE) acquisition by Roche is still being delayed (October?)

October’s sessions:

Thursday closed POSITIVE with 17 decliners, 25 advancers, 0 flat, 1 reverse merged (HSGX) and 2 acquired (AST & OSIR);

Wednesday closed POSITIVE with 19 decliners, 23 advancers, 0 flat, 1 reverse merged (HSGX) and 2 acquired (AST & OSIR);

Tuesday closed POSITIVE with 9 decliners, 32 advancers, 1 flat, 1 reverse merged (HSGX) and 2 acquired (AST & OSIR);

Monday closed NEGATIVE with 29 decliners, 12 advancers, 1 flat, 1 reverse merged (HSGX) and 2 acquired (AST & OSIR);

Friday closed POSITIVE with 13 decliners, 29 advancers, 0 flat, 1 reverse merged (HSGX) and 2 acquired (AST & OSIR);

Thursday closed POSITIVE with 17 decliners, 23 advancers, 2 flats, 1 reverse merged (HSGX) and 2 acquired (AST & OSIR);

Wednesday closed NEGATIVE with 27 decliners, 12 advancers, 3 flats, 1 reverse merged (HSGX) and 2 acquired (AST & OSIR);

Tuesday closed NEGATIVE with 38 decliners, 4 advancers, 1 flat and 1 reverse merged (HSGX), 2 acquired (AST & OSIR);

Monday closed NEGATIVE with 25 decliners, 17 advancers, 1 flat and 2 acquired (AST & OSIR);

Friday closed POSITIVE with 17 decliners, 24 advancers, 2 flats and 2 acquired (AST & OSIR);

Thursday closed NEUTRAL with 21 decliners, 21 advancers, 1 flat and 2 acquired (AST & OSIR);

Wednesday closed NEGATIVE with 22 decliners, 18 advancers, 3 flats and 2 acquired (AST & OSIR);

Tuesday closed NEGATIVE with 36 decliners, 5 advancers, 2 flat and 2 acquired (AST & OSIR);

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.